Sanne Weijzen, Ph.D., is the Vice President, Corporate Strategy and EU Operations at Neogene Therapeutics. Dr. Weijzen has more than 20 years of combined academic and biotech industry experience. Before joining Neogene, she spent 4 years as a COO of Scenic Biotech, where she was responsible for finance, HR, IP and legal, while building the company from the ground up.
Previously, Dr. Weijzen worked as consultant advising early-stage biotech companies on business strategy, financing, IP, and operations. She started her industry career at Aglaia Biomedical Ventures, investing in early-stage oncology companies, where she ultimately became partner.
Dr. Weijzen earned her master’s degree in Biomedical Sciences from the University of Leiden and did her Ph.D. research at Cardinal Bernadin Cancer Center, Loyola University Chicago in Tumor Immunology in the lab of Prof. Martin Kast. She completed her post-doctoral fellowship in molecular cancer cell signaling at the University of Utrecht.
